best medical therapy

PreclinicalSmall molecule

UUniversity of North Carolina, Chapel Hill

best medical therapy is one of 47 small molecule programs targeting Inflammatory Bowel Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inflammatory Bowel DiseaseActive, not recruiting

Patent Foramen OvaleActive, not recruiting

Inflammatory Bowel DiseasePreclinical

Active, not recruiting

Patent Foramen OvalePhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

151 competitors in Inflammatory Bowel Disease

#DrugCompanyPhaseTrials

Remicade

OOrganon and Co

Phase 3

17 2

Stelara

Johnson & Johnson

Phase 3

1 3

Thalomid

Bristol-Myers Squibb

Phase 3

1 4

Farxiga

AstraZeneca

Phase 3

1 5

Humira

CCelltrion

Phase 3

7 6

Omvoh

Eli Lilly

Phase 3

—7

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 8

Deltavit

HHyundai Pharmaceutical Co., LTD.

Jyseleca

1 10

Iron Sulphate

PPierre Fabre Pharma GmbH

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Inflammatory Bowel Disease1 trial

Response To Medical Therapy in Inflammatory Bowel Disease Patients Carrying-out a Prescribed Exercise Programme

Unknown status·RRoyal College of Surgeons, Ireland·N/A·NCT05174754·70 enrolled

Patent foramen ovale1 trial

Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)

Unknown status·NNMT Medical·Phase 2/3·NCT00201461·900 enrolled

Occlusion1 trial

Carotid Occlusion Surgery Study

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 3·NCT00029146·700 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for best medical therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — best medical therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for best medical therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of North Carolina, Chapel Hill company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of North Carolina, Chapel Hill

best medical therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Inflammatory Bowel Disease1 trial

Patent foramen ovale1 trial

Occlusion1 trial

References

Drug Info

Quick Facts

Related News